People · Operator

Gregory H. Ekizian

Named in public records as an officer, director or promoter · active 2016–2016 · Biotechnology

1
Companies
3
Filings
$9.4M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Protagenic Therapeutics, Inc.\newBiotechnologySeries A$9.4M$24.2M2016
Operator network

Gregory H. Ekizian at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Mark Dyne · 6 companies · 1 sharedMark DyneRobert B. Stein · 5 companies · 1 sharedRobert B. SteinGaro H. Armen · 3 companies · 1 sharedGaro H. ArmenLawrence Burstein · 3 companies · 1 sharedLawrence BursteinAlexander K. Arrow · 2 companies · 1 sharedAlexander K. ArrowBrian J Corvese · 1 companies · 1 sharedBrian J CorveseJerome Chazen · 1 companies · 1 sharedJerome ChazenJoshua B Silverman · 1 companies · 1 sharedJoshua B SilvermanJoshua K. Silverman · 1 companies · 1 sharedJoshua K. Silverm…Khalil B. Barrage · 1 companies · 1 sharedKhalil B. BarrageRaymond Musci · 1 companies · 1 sharedRaymond MusciRobert H. Ziroyan · 1 companies · 1 sharedRobert H. ZiroyanStuart Goldfarb · 1 companies · 1 sharedStuart GoldfarbThomas Plotts · 1 companies · 1 sharedThomas PlottsProtagenic Therapeutics, Inc.\new · $9.4M raisedProtagenic Therapeuti…Gregory H. EkizianGE
Gregory H. Ekizian Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Gregory H. Ekizian on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Mark Dyne16
Robert B. Stein15
Garo H. Armen13
Lawrence Burstein13
Alexander K. Arrow12
Raymond Musci11
Stuart Goldfarb11
Jerome Chazen11
Khalil B. Barrage11
Joshua K. Silverman11
Robert H. Ziroyan11
Joshua B Silverman11
Thomas Plotts11
Brian J Corvese11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.